| Patent Number |
Title Of Patent |
Date Issued |
| 7160910 |
Anti-sickling agents |
January 9, 2007 |
| The provides compounds for the treatment of sickle-cell disease. In particular, the invention provides 5-membered heterocyclic anti-sickling agents that are highly effective and non-toxic, and methods for their use. The compounds include analogues and derivatives of naturally occurri |
| 7119208 |
Anti-sickling agents |
October 10, 2006 |
| Compounds for the treatment of sickle-cell disease, and methods for their use are provided. The compounds have a dual mode of action. First, binding of the compounds to hemoglobin increases the oxygen affinity of both normal and sickle hemoglobin. Secondly, binding of these compounds |
| 6894185 |
Substituted chiral allosteric hemoglobin modifiers |
May 17, 2005 |
| A family of substituted chiral allosteric effectors of hemoglobin is useful for delivering more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood. |
| 6534501 |
Allosteric inhibitors of pyruvate kinase |
March 18, 2003 |
| Chemical structures have been identified which allosterically modify pyrvate kinase and inhibit enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, such as the |
| 6486342 |
Substituted chiral allosteric hemoglobin modifiers |
November 26, 2002 |
| A family of substituted chiral allosteric effectors of hemoglobin is useful for delivering more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood. |
| 6214879 |
Allosteric inhibitors of pyruvate kinase |
April 10, 2001 |
| Chemical structures have been identified which allosterically modify pyrvate kinase and either inhibit or activate enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is |
| 5927283 |
Allosteric modifiers of hemoglobin |
July 27, 1999 |
| A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The effect has particular application in a wide variety of treatments including hypoxia, hypothermia, ischemia, stroke, ARDS, COPD, surgical blood loss, acute nonvolem |
| 5872282 |
Allosteric modifiers of hemoglobin |
February 16, 1999 |
| A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the |
| 5827888 |
Perinatal treatment of a fetus to avoid oxygen deprivation |
October 27, 1998 |
| A method of using allosteric hemoglobin modifier compounds which promote the release of oxygen to improve delivery of oxygen from the mother to the fetus and the release of oxygen to tissues from fetal hemoglobin in treatment of maternal and fetal related syndromes. |
| 5731454 |
Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen c |
March 24, 1998 |
| A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the |
| 5705521 |
Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogen |
January 6, 1998 |
| A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The effect has particular application in radiation oncology applications. The compounds are capable of acting on hemoglobin in whole blood. |
| 5677330 |
Medical uses of allosteric hemoglobin modifier compounds in patient care |
October 14, 1997 |
| A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The effect has particular application in a wide variety of treatments including hypoxia, hypothermia, ischemia, stroke, ARDS, COPD, surgical blood loss, acute nonvolem |
| 5668182 |
Method of calming or sedating an animal with a hydroxy benzaldehyde compound |
September 16, 1997 |
| Various hydroxy benzaldehyde derivatives including Vanillin, a natural product derived from the vanilla bean that is commonly used as a flavoring agent, is administered by injection (i.v., i.m., s.c., and the like) or intravenous infusion in an effective dose amount to a patient in need |
| 5661182 |
Method for lowering oxygen affinity of hemoglobin in redcell suspensions, in whole blood and in |
August 26, 1997 |
| Drug compounds are used as allosteric modifiers of hemoglobin present in red blood cells. The compounds bind to only a single pair of symmetry related sites in the central water cavity of hemoglobin at the Lys 99.alpha., Arg 141.alpha., and Asn 108 .beta. residues. When one of the dr |
| 5648375 |
Use of hydrophobic compounds and anesthetics in combination with allosteric hemoglobin modifiers |
July 15, 1997 |
| Allosteric hemoglobin modifier compound activity on p50 is potentiated by using the compound in combination with a hydrophobic compound such as an anesthetic. |
| 5599974 |
Aldehydic agents for allosteric modification of hemoglobin |
February 4, 1997 |
| Chemical compounds which interact inside the central water cavity of hemoglobin and bridge between the two .alpha. subunits can be used to allosterically modify hemoglobin towards tense and relaxed states. The functional groups employed are aldehydes and carboxylic acids, wherein the |
| 5591892 |
Allosteric modifiers of hemoglobin |
January 7, 1997 |
| A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the |
| 5432191 |
Allosteric hemoglobin modifiers to decrease oxygen affinity in blood |
July 11, 1995 |
| A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the |
| 5382680 |
Allosteric hemoglobin modifier compounds |
January 17, 1995 |
| Allosteric hemoglobin modifier compounds having the general structural formula: ##STR1## wherein the R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 moieties may be hydrogen, halogen or alkyl groups and may be the same or different, and wherein the R.sub.7 and R.sub.8 moieties ma |
| 5290803 |
Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood |
March 1, 1994 |
| A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the |
| 5250701 |
Allosteric hemoglobin modifiers which decrease oxygen affinity in blood |
October 5, 1993 |
| A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the |
| 5248785 |
Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood |
September 28, 1993 |
| A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the |
| 5122539 |
Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carr |
June 16, 1992 |
| Compounds of the general structural formula: ##STR1## wherein X, Y and Z may each be CH.sub.2, NH, or O, R.sub.2-6 are either hydrogen, halogen, or a substituted or unsubstituted C.sub.1, C.sub.2, or C.sub.3 alkyl group and these moieties maybe the same or different, or alkyl moi |
| 5049695 |
Allosteric hemoglobin modifiers |
September 17, 1991 |
| Allosteric hemoglobin modifier compounds having the general formula ##STR1## wherein X and Z may be CH.sub.2, NH or O. |
| 4887995 |
Method of treating sickle cell anemia |
December 19, 1989 |
| A method of treating a person for sickle cell anemia including administering to the patient's blood a therapeutically effective dosage of ethacrynic acid. The dosage may be administered to blood removed from the patient which blood after addition of the compound is restored to the pa |
| 4795627 |
Tritium labelled N-mustard type compounds and a process for their production |
January 3, 1989 |
| The present invention describes novel tritium labelled nitrogen mustard type compounds, and their aziridinium type analog, and a process for the production of same. The compounds are of value in medical research and development and also as active ingredients of pharmaceutical composition |
| 4751244 |
Compounds useful in treating sickle cell anemia |
June 14, 1988 |
| The present invention is directed to compounds of the general formula I and pharmaceutically acceptable salts thereof: ##STR1## wherein: R.sup.1 =HO or HOOC(CH.sub.2).sub.x CHR.sup.2 NH--;R.sup.2 =H, lower alkyl, benzyl or --CH.sub.2 OH;x=0 or 1;A=--(CH.sub.2).sub.n -- or ##STR2## |
| 4731473 |
Compounds useful in treating sickle cell anemia |
March 15, 1988 |
| The present invention is directed to compounds of the general formula I and pharmaceutically acceptable salts thereof: ##STR1## wherein: R=ethyl, propyl or isopropyl; andA=(CH.sub.2).sub.n wherein n is 2, 4 or 5, and C(CH.sub.2).sub.3. |
| 4731381 |
Method of treating a person for sickle cell anemia |
March 15, 1988 |
| The present invention is directed to a method of treating a person for sickle cell anemia comprising administering to the person a therapeutically effective dosage of a compound of the general formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein: R=ethyl, p |
| 4704402 |
Method of treating sickle cell anemia |
November 3, 1987 |
| A method of treating a person for sickle cell anemia including administering to the person a therapeutically effective dosage of the compound ##STR1## wherein at least one R=Cl, BR, CH.sub.3 or OCH.sub.3 and each other R=H, R'=H or CH.sub.3 and n=1, 2, 3, 4 or 5. The compound is |
| 4699926 |
Compounds useful in treating sickle cell anemia |
October 13, 1987 |
| The present invention is directed to compounds of the general formula I and pharmaceutically acceptable salts thereof: ##STR1## wherein R=H or lower alkyl;R'=H, lower alkyl, benzyl, CH.sub.2 OH;A=(CH.sub.2).sub.1 to 5, >C(CH.sub.3).sub.2, >C (CH.sub.2).sub.3 ; andX=0 or 1.The prese |
| 4482571 |
Sickle cell anemia treatment and compound |
November 13, 1984 |
| A method of treating a person for sickle cell anemia including administering a therapeutically effective dosage of the compound ##STR1## wherein at least one R=Cl, Br, CH.sub.3 or OCH.sub.3 and all the remaining R=H, R'=H or CH.sub.3 and n=1, 2, 3, 4 or 5. Among the preferred species |
